NATIONAL HARBOR, Md.—Black hemodialysis (HD) patients with anemia require relatively more epoetin than their non-black counterparts to achieve similar hemoglobin (Hb) levels, but blacks and non-blacks required similar peginesatide doses, according to findings presented at the National Kidney Foundation 2012 Spring Clinical Meetings.
Peginesatide recently was FDA-approved in the United States for the once-monthly treatment of anemia in adult dialysis patients.
The findings are based on a post-hoc subgroup analysis of data from two phase 3 trials comparing peginesatide and epoetin. The trials had shown peginesatide to be noninferior to epoetin in maintaining Hb levels in HD patients.
The subgroup analysis, by Amit Sharma, MD, Director of Clinical Research at Boise Kidney & Hypertension Institute in Meridian, Idaho, and colleagues examined data from 399 blacks and 666 non-blacks who received peginesatide and 211 blacks and 331 non-blacks who received epoetin. Patients received treatment for 52 or more weeks.
The median weight-adjusted peginesatide dose during the evaluation period (weeks 29-36) was similar for blacks and non-blacks, whereas blacks received 31% higher median doses of epoetin than non-blacks.